TEL AVIV, Israel, April 09, 2025 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (NASDAQ:REE), an automotive technology company that develops and builds software-defined electric vehicles, is the recipient of Frost & Sullivan's 2025 Company of the Year award in the North American Electric Medium-Duty Vehicle Platform Industry category. The award honors REE for its innovative software-defined modular platform, which delivers scalable and flexible solutions to help OEMs and fleet operators address major challenges in ...

TEL AVIV, Israel, April 09, 2025 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (Nasdaq: REE), an automotive technology company that develops and builds software-defined electric vehicles, is the recipient of Frost & Sullivan's 2025 Company of the Year award in the North American Electric Medium-Duty Vehicle Platform Industry category. The award honors REE for its innovative software-defined modular platform, which delivers scalable and flexible solutions to help OEMs and fleet operators address major challenges i ...

Core Viewpoint - An all-former-Kraken team has acquired majority ownership in Janover Inc., aiming to bridge the liquidity gap between Traditional Finance and Decentralized Finance, with a focus on implementing a digital asset treasury strategy centered on Solana [1][6]. Company Overview - Janover Inc. (NASDAQ:JNVR) is an AI-powered online platform that connects the commercial real estate industry, providing data and software subscriptions as well as value-add services to property professionals [9]. - The company serves over one million web users annually, including property owners, developers, and various lenders, facilitating billions of dollars in debt financing each year [10][11]. Leadership Changes - Joseph Onorati has been appointed as Chairman and CEO, while Parker White takes on the roles of Chief Investment Officer and Chief Operating Officer. Blake Janover and William Caragol will remain on the board, with Marco Santori joining as a new board member [2]. Treasury Policy and Digital Assets - The Board has adopted a treasury policy allocating its principal holding to digital assets, starting with Solana (SOL). The company plans to acquire Solana validators and stake SOL to generate revenue for further acquisitions [3][12]. - Staking on Solana is identified as a multi-billion dollar business, with validators playing a crucial role in transaction validation and network consensus [4]. Business Model Transition - Janover will continue its transition to a Software as a Service (SaaS) business model, with key personnel remaining involved in daily operations to maintain service quality [5]. Future Growth and Strategy - The company aims to provide investors with economic exposure to the Solana ecosystem through its new treasury policy, marking a significant step in mass DeFi adoption [6][12]. - The leadership team brings extensive experience in digital assets, trading, and operations, positioning the company for future growth [7]. Name and Ticker Change - As part of the acquisition, Janover will undergo a name and ticker symbol change, transitioning to DeFi Development Corporation at a future date [8].

Core Insights - Veeva Systems has announced the launch of Veeva SiteVault CTMS, a clinical trial management system designed to enhance research site efficiency and integrate seamlessly with sponsors [1][2] - The system will be available for free to over 90% of research sites, specifically those managing up to 20 concurrent active studies, with an initial release planned for August 2025 [2] Group 1: Product Features and Benefits - Veeva SiteVault CTMS integrates with SiteVault eISF and SiteVault eConsent, allowing comprehensive management of clinical trials within a single system [1] - The integration with Veeva's Clinical Platform facilitates seamless bidirectional data flow between sites and sponsors, reducing manual processes and increasing efficiency [1][2] - The streamlined user experience provided by Veeva SiteVault is expected to enhance the speed of clinical trials, benefiting patients [2] Group 2: Company Commitment and Market Position - Veeva Systems is recognized as the global leader in cloud software for the life sciences industry, serving over 1,000 customers, including major biopharmaceutical companies and emerging biotechs [3] - As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, and shareholders [3]

Core Insights - VERSES AI Inc. has commenced trading its Class A Subordinate shares on the OTCQB market under the symbol "VRSSD" as part of its strategy to prepare for an uplisting to Nasdaq [1] - The company must receive approval for its listing application from Nasdaq and meet specific pricing and financing conditions before the uplisting can occur [2] Company Overview - VERSES is a cognitive computing company focused on developing next-generation intelligent software systems inspired by natural principles [3] - The flagship product, Genius,™ is designed for machine learning practitioners to model complex dynamic systems and create autonomous intelligent agents [3] Future Plans - The company anticipates listing its Class A Subordinate Voting shares on Nasdaq, contingent upon meeting the necessary conditions and receiving approval [5][6]

Paysign, Inc. (NASDAQ:PAYS) Q4 2024 Earnings Conference Call March 25, 2025 5:00 PM ET Company Participants Mark Newcomer - President and CEO Jeff Baker - CFO Matt Turner - President, Patient Affordability Matt Lanford - CPO Conference Call Participants Jacob Stephan - Lake Street Capital Markets Gary Prestopino - Barrington Research Peter Heckmann - D.A. Davidson Operator Good afternoon. My name is Kevin and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Paysign, ...

Luminar (LAZR) Q4 2024 Earnings Call March 20, 2025 05:00 PM ET Company Participants Aileen McAdams - Head of Investor Relations Austin Russell - Founder & Chief Executive Officer Tom Fennimore - CFO Jash Patwa - Equity Research Associate Winnie Dong - Director, Equity Research Federico Merendi - Equity Research Associate Tyler Anderson - Equity Research Associate Conference Call Participants Morgan Long - Analyst Aileen McAdams Welcome, everyone, to Luminar's fourth quarter of twenty twenty four business u ...

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was $5.4 million, an increase of 14% compared to Q4 2023, while full-year revenue reached $19.6 million, up from $17.3 million in 2023 [34] - Annual Recurring Revenue (ARR) grew to $9.8 million at the end of Q4 2024, up from $8.8 million at the end of Q4 2023, reflecting strong customer demand [31] - Gross profit margin for Q4 2024 was 86%, down from 91% in Q4 2023, primarily due to a one-time benefit in Q4 2023 and amortization of cloud product costs [36] Business Line Data and Key Metrics Changes - Product revenue for Q4 2024 was $3.7 million, a 24% increase year-over-year, while service revenue remained flat at $1.7 million [34] - Maintenance Services ARR declined to $6.4 million from $7.1 million year-over-year, driven by customer migration to subscription and cloud offerings [32] - Subscription ARR increased to $2.6 million from $1.7 million year-over-year, indicating a successful transition to recurring revenue models [32] Market Data and Key Metrics Changes - The adoption of AI in breast cancer detection is still low, with only 37% of mammography sites in the U.S. currently utilizing AI, but this is expected to change as providers recognize the benefits [8] - The company closed 106 deals in Q4 2024, including 54 perpetual, 33 subscription, and 19 cloud deals, indicating a growing preference for cloud solutions [12] Company Strategy and Development Direction - The company is focused on expanding its SaaS footprint and driving innovation in AI solutions, positioning itself for long-term growth [12][18] - The transition to a recurring revenue model is expected to enhance financial predictability and stability, despite potential short-term impacts on GAAP revenue recognition [21][22] - Partnerships with organizations like Olea and Koios Medical are aimed at enhancing the end-to-end AI-powered approach to breast cancer screening and detection [14][65] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term benefits of the SaaS transition, despite acknowledging short-term headwinds to revenue and cash flow [29][30] - The company anticipates continued momentum in cloud adoption and regulatory approvals, positioning itself to capture a growing share of the market [103][104] Other Important Information - The company received FDA clearance for ProFound Detection version 4.0, which improves cancer detection and reduces false positives, enhancing workflow efficiency [10][11] - The ProFound Cloud platform processed nearly 100,000 cases in its first two quarters of availability, demonstrating rapid adoption [24] Q&A Session Summary Question: Outlook for CapEx environment and cloud deal count - Management noted that Q4 had strong execution by the sales team, with some deals pulled forward from Q1, and expects continued momentum in cloud adoption [42][44] Question: Early reactions to ProFound Detection version 4.0 - Management reported that the accuracy of version 4.0 is performing better in clinical practice than during FDA submission, indicating positive early feedback [46][48] Question: Impact of partnerships on business - Management explained that partnerships are driven by customer requests and are aimed at enhancing the patient care journey, with ongoing evaluations of market dynamics [64][66] Question: Operating expenses outlook - Management indicated that operating expenses may not remain flat and that there are several initiatives planned for the future [72][75] Question: ARR dynamics and future growth - Management expects continued growth in ARR driven by cloud business and a shift in deal mix towards subscription and cloud offerings [79][80] Question: Adoption impact of ProFound Detection version 4.0 - Management anticipates better adoption due to improvements in accuracy and workflow efficiency, addressing customer requests [81][84] Question: Maintenance and support for version 4.0 - Customers current on maintenance agreements will receive the new version, while those not current will incur a fee to update [88][89]

iCAD (ICAD) Q4 2024 Earnings Call March 19, 2025 04:30 PM ET Company Participants Rosalyn Christian - Investor RelationsDana Brown - President, CEO & Chairman of the BoardEric Lonnqvist - CFOMarie Thibault - Managing Director Conference Call Participants Per Ostlund - Research AnalystYale Jen - Senior Managing Director & Senior Biotech AnalystGene Mannheimer - Managing Director, Senior Research Analyst Operator Greetings. Welcome to the iCAD Inc. Fourth Quarter and Full Year twenty twenty four Financial Res ...

StoneCo (STNE) Q4 2024 Earnings Call March 18, 2025 05:00 PM ET Company Participants Pedro Zinner - Chief Executive OfficerLia Machado de Matos - Strategy & Marketing OfficerMateus Scherer Schwening - CFO & IROMario Pierry - Managing DirectorTito Labarta - Vice PresidentYuri Fernandes - Executive Director Conference Call Participants Eduardo Rosman - AnalystDaniel Vaz - Lead Analyst - Equity ResearchRenato Meloni - Senior AnalystJames Friedman - Financial Analyst Operator Good evening, everyone. Thank you f ...